Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP

Leuk Lymphoma. 2005 Apr;46(4):549-52. doi: 10.1080/10428190400029841.

Abstract

Sixteen patients with relapsed mantle-cell lymphoma (MCL) were treated with the combination of fludarabine and cyclophosphamide (FC) with or without rituximab. All patients had received prior CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) chemotherapy, with a response rate of 63.5% (25% complete response), and a median duration of response of 10 months (range 1-32 months). Subsequent treatment with FC +/- rituximab produced a response rate of 75% with a higher complete response rate (56% P = 0.07 vs. CHOP), and a median duration of response of 11 months (4-25+ months). This study demonstrates that FC is a highly active regimen in patients relapsing following CHOP chemotherapy.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cyclophosphamide / administration & dosage*
  • Cyclophosphamide / therapeutic use
  • Disease-Free Survival
  • Doxorubicin / therapeutic use
  • Humans
  • Lymphoma, Mantle-Cell / drug therapy*
  • Middle Aged
  • Prednisone / therapeutic use
  • Recurrence
  • Remission Induction
  • Retrospective Studies
  • Rituximab
  • Treatment Outcome
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives*
  • Vincristine / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Vidarabine
  • fludarabine
  • Prednisone

Supplementary concepts

  • CHOP protocol